Differences in HDL-associated ApoC-III sialylation status have also been found to be associated with differences in HDL immunomodulatory capacity in stimulated monocytes (Watanabe et al., 2006), and in individuals with vs. without metabolic syndrome (Savinova et al., 2014). Here, APOC3 is linked to metabolic syndrome.